R-Pharm and Beijing Health Guard Biotechnology Agreed to Collaborate on Nonvalent HPV Project

| By | HPV, R-Pharm, Vaccination
0
202

The two companies aim to develop and commercialize a nonavalent HPV vaccine in Russia to help prevent HPV infections and associated diseases, especially cervical cancer.

At the East Economic Forum 2019 held in Vladivostok, Russia, R-Pharm Group, a leader of the Russian healthcare market, and Beijing Health Guard Biotechnology, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel protein-based biologics against infectious diseases, signed an agreement of intent to collaborate on a nonavalent HPV (human papillomavirus) project. The vaccine developed by Beijing Health Guard includes as antigens virus-like particles of nine high-risk HPV types that combined are responsible for ~90% of cervical cancer cases worldwide.

Both parties articulated their deep interest in a development and commercialization collaboration for the nonavalent HPV vaccine to help eliminate human papillomavirus infections and associated diseases in the Russian Federation. The letter of intent was signed by the chairman of the board of R-Pharm Group, Mr. Alexey Repik, and chairman of the board of Beijing Health Guard, Mr. Chunli Hao.

”It is of the utmost importance to make innovative HPV vaccines available to all Russian citizens. This virus provokes genetic mutations leading to cervical cancer, one of the most widely spread oncological diseases in Russia. I strongly believe, that the high-tech product of our partner will help us improve the healthcare system and defeat this dangerous virus once and for all”,

said Mr. Alexey Repik.

“Beijing Health Guard remains dedicated to the development of innovative protein-based biologics, specifically vaccines, for the protection against infectious diseases in China and around the globe. We are excited to partner with R-Pharm Group on the further development and potential commercialization of our nonavalent HPV vaccine in Russia, where HPV infections and diseases it causes, in particular, cervical cancer, continue to pose a significant public health burden”,

stated Mr. Hao.

“Collaboration between Beijing Health Guard and R-Pharm Group on the HPV vaccine project amounts to an incredible synergy of technology and market, which will allow us to bring our quality yet a cost-effective vaccine to Russian citizens in need, thereby contributing to the Russian public health. We also believe this will only be a start to a potentially more extensive collaboration in the future between the parties that in turn will drive further exchange and cooperation between Chinese and Russian pharmaceutical industries, enriching the strategic partnership between China and Russia.”

SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.